RecruitingNCT05010603
Late Onset Alzheimer's Disease
Sponsor
Columbia University
Enrollment
10,000 participants
Start Date
Nov 15, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.
Eligibility
Min Age: 55 Years
Inclusion Criteria5
- Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases.
- a living sibling with probable or possible AD;
- a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older);
- participants in the proband's generation with an identified companion serving as an informant;
- participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent.
Exclusion Criteria6
- failure to identify an appropriate informant;
- uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder;
- discovery of additional diagnosis that could account for the clinical manifestations;
- unwillingness to participate;
- failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD);
- participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.
Interventions
GENETICBlood Draw
Collection of blood samples for genetic testing
OTHERLate Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
Memory Test
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05010603
Related Trials
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT064675391 location
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229241 locations
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
NCT071782101 location
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT041233141 location
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787278 locations